SALT LAKE CITY, April 24, 2018 -- Nu-Med Plus, Inc. (OTCBB:NUMD), a medical device development company, announced that on April 10, 2018, shareholders voted to re-elect all the existing highly qualified directors, Jeffrey Robins, William Moon, Thomas Tait, Dr. Craig Morrison and Dr. Brett J. Earl, to the Nu-Med Plus Board of Directors.
Sadler, Gibb and Associates LLC was also reaffirmed to serve as Nu-Med's independent registered public accounting firm and auditor.
Jeff Robins, Chairman of the Board and CEO of Nu-Med Plus, Inc., remarked, "I greatly appreciate the strong support from our shareholders and the reaffirmation of their confidence in the Board and our management team by re-electing all 5 of our incumbent directors. This strong vote of confidence recognizes their hard work and relentless focus since the inception of our company. We are more energized than ever about building on Nu-Med's strengths to anticipate and deliver our INO products to the medical community. We plan to maintain an active and productive dialogue with shareholders as we continue to transform our business and create value for all of our stakeholders."
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed Nitric Oxide technologies. The emphasis is to generate controlled-flow of INO for internal therapies with integrating accessories for availability in hospitals, emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries. For more company information please visit www.nu-medplus.com.
Contact: Keith Merrell/CFO (801) 746 3570
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.


Luxshare Shares Rise as First-Half Profit Jumps 18%
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China
Google Expands Gemini Enterprise With AI Tools for Legal Sector
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny
Bathla Group Hires Administrators as Australia Housing Slump Deepens
Mercer International Stock Surges 45% on C$20 Million Canada Funding
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
Nvidia Options Price in $280 Billion Earnings Swing
Tesla Raises Cybertruck Prices by $5,000 in US
SK Hynix Shares Fall as Workers Reject Wage Deal
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 



